文献速递系统性红斑狼疮

改良ALMS与BLISS标准在两家美国医疗系统中评估标准治疗下狼疮肾炎疗效的表现

Performance of Modified ALMS and BLISS Criteria with Standard of Care Treatment in Two US Health Care Systems.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-01-31

这项回顾性队列研究纳入173例活检证实的III或IV型±V型狼疮肾炎患者(77.5%为黑人),按改良ALMS和改良BLISS标准评估12个月完全缓解率分别为20.6%和33.7%。商业保险、白蛋白升高和低C4与mBLISS完全缓解相关,非商业保险患者3年ESRD累积发生率高于商业保险患者,ESRD和死亡发生率超过对照临床试验。

要点

  • 12个月mALMS完全缓解率20.6%,mBLISS完全缓解率33.7%。
  • 商业保险者mBLISS完全缓解率更高(调整CR比3.5)。
  • 非商业保险者3年ESRD累积发生率30.4%,高于商业保险者12.7%。

核心结论

  • 在以黑人为主、无保险的狼疮肾炎人群中,尽管12个月完全缓解率与对照临床试验相似,ESRD和死亡发生率超过含安慰剂对照组的临床试验。

研究设计与样本

  • 回顾性队列研究,纳入173例活检证实的III或IV型±V型狼疮肾炎患者,入组时尿蛋白与肌酐比值≥1gm/gm且估算肾小球滤过率>50 ml/min/1.73 m2。
  • 采用多变量Cox回归分析与完全缓解相关的临床、治疗和实验室因素。

主要发现

  • 12个月时20.6%(95%CI 14.6-28.6%)达到mALMS完全缓解,33.7%(95%CI 26.4-42.4%)达到mBLISS完全缓解。
  • 与mBLISS完全缓解相关的因素包括商业保险(调整CR比=3.5,95%CI 1.9-6.7,P<0.001)、白蛋白每升高1 gm/dl(调整CR比=1.8,P=0.02)和低C4(调整CR比=2.6,P=0.03)。
  • 3年ESRD累积发生率为23.1%(95%CI 15.7-31.3%),死亡累积发生率为6.1%(95%CI 2.8-11.1%)。
  • 非商业保险患者ESRD累积发生率为30.4%(95%CI 19.6-41.9%),商业保险患者为12.7%(95%CI 5.0-24.2%),P=0.024。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A retrospective cohort study was undertaken in a predominantly Black population undergoing standard treatment for lupus nephritis (LN) to estimate the incidence of, and risk factors for, complete response (CR) according to modified Aspreva Lupus Management Study (mALMS) and modified Belimumab International Study in Lupus Nephritis (mBLISS) criteria by 12 months. METHODS: Patients with biopsy-proven LN class III or IV ± V, urine protein-to-creatinine ratio of ≥1gm/gm and estimated glomerular filtration rate of >50 ml/minute/1.73 m2 at the time of the incident LN flare were included. The clinical, treatment, and laboratory factors associated with CR were identified using multivariable Cox regression. RESULTS: Of 173 patients, 86.1% were women, 77.5% were Black, and over half (59.5%) had non-commercial insurance. By 12 months, 20.6% (95% confidence interval (95% CI) 14.6-28.6%) achieved mALMS CR and 33.7% (95% CI 26.4-42.4%) achieved mBLISS CR. Factors associated with mBLISS CR were commercial insurance (adjusted CR ratio = 3.5 [95% CI 1.9-6.7]; P < 0.001), albumin (adjusted CR ratio = 1.8 per 1 gm/dl increase in albumin; P = 0.02), and low C4 (adjusted CR ratio = 2.6; P = 0.03). Cumulative incidence of end-stage renal disease (ESRD) at 3 years was 23.1% (95% CI 15.7-31.3%) and 6.1% (95% CI 2.8-11.1%) for death. Patients with non-commercial insurance were more likely to develop ESRD, with cumulative incidence of 30.4% (95% CI 19.6-41.9%) compared to 12.7% (95% CI 5.0-24.2%) for patients with commercial insurance (P = 0.024). CONCLUSION: In a primarily Black, uninsured LN population, despite achieving similar CR rates at 12 months, the incidence of ESRD and death exceeded those observed in controlled clinical trials with placebo arms.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Khosroshahi A, Tong D, Bao G, et al. Performance of Modified ALMS and BLISS Criteria with Standard of Care Treatment in Two US Health Care Systems. Arthritis Care Res (Hoboken). 2023. PMID: 36121035. doi:10.1002/acr.25025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。